96 JC02 Rec d PCT/PTO

EXPRESS MAIL LAB

NO.: EV517776154US



PATENT

Attorney Docket No. 27763-705.831

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Richard O. Chen et al.

Application No.: 10/502,420

Filed: July 23, 2004

Title Drug Discovery Method

al. OTPE

PATENT APPLICATION

Art Unit: Not yet assigned

Examiner: Not yet assigned

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

apply):		tatemen	t c fies under 37 C.F.R. §1.97, subsection ecause (check all that			
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR			
		(2)	It is being filed within 3 months of entry of a national stage OR			
	\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits OR			
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.			
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:					
		a certif	ication as specified in §1.97(e) is provided below; or			
			f \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included the payment of other papers filed together with this statement.			
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:					
	A.	a certif	ication as specified in §1.97(e) is completed below; and			
	B.	-	ion under 37 C.F.R. §1.97(d) requesting consideration of this statement is ted herewith; and			
	C.		of \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or ed with the payment of other papers filed together with this statement.			
\boxtimes	Copies herewi		h of the references listed on the attached Form PTO-1449 are enclosed			
\boxtimes	-	of ref PT THA	Gerences listed on the attached Form PTO-1449 are enclosed herewith AT:			
		referen	w of the voluminous nature of references, and the likelihood that these ces are available to the Examiner in the file history of the parent ation (Serial No.), copies are not enclosed herewith.			
		-	of the foregoing publications are not available to the Examiner, Applicant deavor to supply copies at the Examiner's request.			
	\boxtimes	accord	of only foreign patent documents and non-patent literature are enclosed in ance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent ation publication listed on the attached Form PTO-1449 are not enclosed			

·		internation application has entered	on was filed aft tune 30, 2003 or this the national stage under 35 USC §371 after frequirement under 37 CFR 1.98 (a)(2)(i).				
		There are no listed references which	are not in the English language.				
		The relevance of those listed reference as follows:	nces which are not in the English language is				
		Attached are copies of search report which are listed on the attached Subi	e(s) from corresponding patent application(s), mission Under MPEP 609 D.				
			ished pending patent applications which may ed on the attached Submission Under MPEP				
\boxtimes	referen	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.27763-705.831).					
	·		Respectfully submitted,				
			WILSON SONSINI GOODRICH & ROSATI				
Dated:		6 10 05	By: C A . i. C				
		\	Anie K. Roche				
	ige Mill	94304-1050					
	193 - 930						
` '		021971					

10502420 - GALL: 1631

PTO/SB/08A (08-03)
Approve through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Ornec; U.S. DEPARTMENT OF COMMERCE

 Under the	paperwork Rec	luction A	of 011991 no person	s required to respond to a collection of inf	ormation unless it contains a valid OMB control number
)'' - 4g/	Con	nplete if Known
Substitute fo	or form 1449	л то	3	Application Number	10/502,420
INFORM	[ATION]	disc:	nd sure	Filing Date	July 23, 2004
DIALLY	IENI DX	ACL	LICANI	y i not ramed inventor	Richard O. Chen et al.
(Use as	many sheet.	s as	cessary)	Art Unit	Not yet assigned
			HADE	Examiner Name	Not yet assigned
Sheet	1	of	2	Attorney Docket Number	27763-705.831

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
-		US-				
		US-				
		US-			·	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ¢	
/LC/		EP1158447 A1	11-28-2001	Ralf Zimmer et al.			
/LC/		WO 01/55911 A1	8-2-2001	Vadim Babenko			
	ļ					-	
			L		1		

Examiner Signature /Lori Clow/ Date Considered 05/16/2009

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approve see through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Omee; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction s required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449 PTO JUN 1 0 2005 Application Number 10/502,420 INFORMATION DISCLOSURE STATEMENT BY ASPLICANT (Use as many sheets as necessary) Filing Date July 23, 2004 Richard O. Chen et al. First Named Inventor Art Unit Not yet assigned Not yet assigned **Examiner Name** - F 27763-705.831 Attorney Docket Number 2 Sheet 2 of

		NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/LC/		Jacques van Helden et al., Representaing and Analysing Molecular and Cellular Function Using the Computer, Biol. Chem,XP008032491, September/October 2000, Vol. 381, pp. 921-935, Walter de Gruyter, Berlin & New York	-
/LC/		Diane E. Oliver et al., Ontology Development For A Pharmacogenetics Knowledge Base, Stanford Medical Informatics, Stanford University of Medicine, January 23, 2002, pp. 65-76, XP002287419, Retrieved from Internet: <u>URL:http://helix-web.stanford.edu/psb02/o1iver.pdf</u>	
/LC/		Peter D. Karp et al., Integrated pathway-genome databases and their role in drug discovery, Trends in Biotechnology, XP004169726, July 1999, pp. 275-281, Vol. 17, Elsevier Science	
/LC/		Andrey Rzhetsky, Ph.D. et al., A Knowledge Model for Analysis and Simulation of Regulatory networks in Bioformatics Studied Aiming at Disease Gene Discovery, AMIA 99 Fall Annual Symposium, PP1-5, XP002287421, Retrieved from the Internet: URL:http://www.amia.org/pubs/proceedings/symposia/1999/D005314.pdf	-
/LC/		C.A. Goble et al., Transparent Access to Multiple Bioinformatics Information Sources, XP-001116348, IBM Systems Journal, 2001, pp. 532-551, Vol. 40, No. 2, IBM Corp. Armonk, New York	
:			

Examiner	/Lori Claw/	Date	05/16/2000
signature	/Lon Clow/	Considered	03/10/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.